Recent developments in biologic therapies for the treatment of patients with systemic lupus erythematosus.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29660084.
- Also identified by DOI 10.1093/rheumatology/key064.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
SLE has a complex pathogenesis, and multiple therapeutic targets have been discovered in recent years. In spite of belimumab being approved by the US Food and Drug Administration and the widespread use of rituximab, there have been many failed attempts to treat SLE successfully using biologic agents. In this review, we consider newer biologic approaches that might offer the hope of improving the outcome of SLE patients. These include the fully humanized anti-CD20 mAbs, PEGylated anti-CD40L, IFNα inhibitors, rigerimod and immune complexes blockade.
Medical subject headings
- Biological Products
- Immunologic Factors
- Lupus Erythematosus, Systemic